Related Experiment Videos

Malignant diseases after allogeneic bone marrow transplantation: the case for assessment of risk factors

G Socié¹, H J Kolb, P Ljungman

¹Bone Marrow Transplant Unit, Hôpital Saint Louis, Paris, France.

British Journal of Haematology

|April 1, 1992

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Non-myeloablative versus reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients aged ≥65: a study from the ALWP of EBMT.

Bone marrow transplantation·2026

Severe corneal manifestations of graft-versus-host disease: Experience of a tertiary referral center.

The ocular surface·2024

Metabolic syndrome and cardiovascular disease after haematopoietic cell transplantation (HCT) in adults: an EBMT cross-sectional non-interventional study.

Bone marrow transplantation·2021

Postremission Consolidation by Autologous Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia in First Complete Remission (CR) and Negative Implications for Subsequent Allogeneic HCT in Second CR: A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2019

Allogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.

Bone marrow transplantation·2019

Management of growth failure and growth hormone deficiency after pediatric allogeneic HSCT: Endocrinologists are of importance for further guidelines and studies.

Pediatric hematology and oncology·2019

See all related articles